10-K: Stoke Therapeutics Reports 2024 Results, Highlights Progress in Dravet Syndrome and ADOA Programs

Stoke Therapeutics' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).

Summary

• Stoke Therapeutics is a late-stage clinical company focused on RNA-based medicines to treat severe diseases.
• The company's lead product candidate, zorevunersen (STK-001), is in late-stage clinical testing for Dravet syndrome, a severe genetic epilepsy.
• A Phase 3 study, EMPEROR, is expected to begin in the second quarter of 2025 to further evaluate the efficacy and safety of zorevunersen in children and adolescents with Dravet syndrome.
• The company has completed Phase 1/2a clinical trials for zorevunersen, which have shown substantial and durable reductions in convulsive seizure frequency and improvements in cognition and behavior.
• STK-002 is the lead clinical candidate for the treatment of Autosomal Dominant Optic Atrophy (ADOA).
• The company has received authorization in the United Kingdom to proceed with a Phase 1 open-label study (OSPREY) of STK-002 in children and adults with ADOA.
• Stoke has a collaboration agreement with Acadia Pharmaceuticals for the discovery, development, and commercialization of novel RNA-based medicines for severe and rare genetic neurodevelopmental diseases.
• On February 14, 2025, Stoke entered into a License and Collaboration Agreement with Biogen for the development and commercialization of zorevunersen and other potential products directed to the SCN1A gene (Dravet syndrome) in all territories worldwide other than the United States, Canada, and Mexico.
• The company's net losses for the years ended December 31, 2024 and 2023 were $89.0 million and $104.7 million, respectively.
• As of December 31, 2024, the company had cash, cash equivalents, and marketable securities of $246.7 million, which, along with the $165 million upfront payment received in March 2025 and other eligible cash flows from the Biogen collaboration, is expected to fund operations to mid-2028.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the company's progress and the challenges it faces. The collaboration with Biogen is a positive development, but the company's ongoing losses and need for additional funding temper the overall outlook.

Positives

• Zorevunersen has received Breakthrough Therapy Designation from the FDA, potentially expediting its development and review.
• The collaboration with Biogen provides significant financial resources and expertise for the development and commercialization of zorevunersen outside of North America.
• Phase 1/2a data for zorevunersen shows promising results in reducing seizure frequency and improving cognitive and behavioral outcomes in Dravet syndrome patients.
• The company has a proprietary TANGO platform that can be applied to a wide range of severe diseases.
• The company has a strong intellectual property portfolio with multi-national issued and pending claims for the TANGO mechanisms and compositions of matter of oligonucleotides.

Negatives

• The company has a history of operating losses and expects to continue to incur losses for the foreseeable future.
• The company will need to raise additional funding before it can expect to become profitable from any potential future sales of zorevunersen, STK-002 or its future product candidates.
• Clinical trials may be delayed or halted by the FDA, foreign regulatory authorities, or an IRB.
• The company is early in its development efforts and may not be able to develop, obtain regulatory approval for and commercialize zorevunersen (STK-001), STK-002 and its future product candidates.

Risks

• Clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA or foreign regulatory authorities.
• The company may not be successful in its efforts to use its TANGO technology to expand its pipeline of product candidates and develop marketable products.
• The company's product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe.
• The commercial success of the company's product candidates will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community.
• The pricing, insurance coverage and reimbursement status of newly approved products is uncertain.
• The company's success depends in part on its ability to obtain, maintain and protect its intellectual property.
• The market price of the company's stock may be volatile.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future and anticipates that its research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapid technological change, competition, and a strong emphasis on intellectual property. Stoke faces competition from companies developing RNA-based treatments and other therapies for genetic diseases.

Comparison to Industry Standards

• The document mentions Sarepta's Exondys 51 (eteplirsen) and Biogen's SPINRAZA as examples of successful rare disease treatments developed by members of Stoke's executive team.
• The document notes that Encoded Therapeutics has started clinical testing of a gene regulation therapy program in Dravet syndrome, which may address the underlying genetic cause of the disease.
• The document mentions that PYC Therapeutics is the only other company with an ongoing clinical program developing a cell penetrating peptide PMO conjugated to ASO for the treatment of ADOA.

Management Changes

Stakeholder Impact

• Shareholders: Dilution from potential future equity offerings.
• Employees: Potential for increased workload and pressure due to company growth.
• Patients: Potential for new treatment options for Dravet syndrome and ADOA.
• Suppliers: Increased demand for manufacturing and research services.
• Creditors: Potential for increased debt financing.

Next Steps

• Initiate the Phase 3 EMPEROR study of zorevunersen in the second quarter of 2025.
• Continue preclinical activities to support understanding of dosing for the Phase 1 OSPREY study and other OPA1 indications.
• Conduct further research to provide a better understanding of the commercial opportunity for STK-002.

Key Dates